Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy

Abstract

Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19) 1 , population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model 2 , which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we outline several scenarios: mass vaccination campaigns with different paces, different transmission rates due to new variants and different enforced countermeasures, including the alternation of opening and closure phases. Our results demonstrate that non-pharmaceutical interventions (NPIs) have a higher effect on the epidemic evolution than vaccination alone, advocating for the need to keep NPIs in place during the first phase of the vaccination campaign. Our model predicts that, from April 2021 to January 2022, in a scenario with no vaccine rollout and weak NPIs ( $${\cal{R}}_0$$ R 0 = 1.27), as many as 298,000 deaths associated with COVID-19 could occur. However, fast vaccination rollouts could reduce mortality to as few as 51,000 deaths. Implementation of restrictive NPIs ( $${\cal{R}}_0$$ R 0 = 0.9) could reduce COVID-19 deaths to 30,000 without vaccinating the population and to 18,000 with a fast rollout of vaccines. We also show that, if intermittent open–close strategies are adopted, implementing a closing phase first could reduce deaths (from 47,000 to 27,000 with slow vaccine rollout) and healthcare system costs, without substantive aggravation of socioeconomic losses.

References 53

1. 1.

   Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur. J. Pharmacol. 2020;889:173644.

   Not in our library10.1016/j.ejphar.2020.173644

2. 2.

   Giordano G, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nat. Med. 2020;26:855-860.

   Not in our library10.1038/s41591-020-0883-7

3. 3.
   A new coronavirus associated with human respiratory disease in China · 2020

   Corrected
4. 4.

   Wang J, Peng Y, Xu H, Cui Z, Williams RO. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020;21:225.

   Not in our library10.1208/s12249-020-01744-7

5. 5.

   Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur. J. Pharmacol. 2021;892:173751.

   Not in our library10.1016/j.ejphar.2020.173751

6. 6.

   Abbasi K. Behavioural fatigue: a flawed idea central to a flawed pandemic response. BMJ. 2020;370:m3093.

   Not in our library10.1136/bmj.m3093

7. 7.

   Rypdal K, Bianchi FM, Rypdal M. Intervention fatigue is the primary cause of strong secondary waves in the COVID-19 pandemic. Int. J. Environ. Res. Public Health. 2020;17:9592.

   Not in our library10.3390/ijerph17249592

8. 8.

   Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603-2615.

   Not in our library10.1056/nejmoa2034577

9. 9.

   Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403-416.

   Not in our library10.1056/nejmoa2035389

10. 10.
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials · 2021

    Corrected
11. 11.

    US Food and Drug Administration. FDA Briefing Document. Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting, February 26, 2021. https://www.fda.gov/media/146217/download

    Not in our library

12. 12.
    First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 · 2021

    No notice
13. 13.
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021

    Corrected
14. 14.

    European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (2021).

    Not in our library

15. 15.

    ANSA. Pfizer vaccine arrives in Italy. https://www.ansa.it/english/news/2020/12/30/pfizer-vaccine-arrives-in-italy_4690fcec-88a8-4919-b821-afc01fc3955a.html (2020).

    Not in our library

16. 16.

    ANSA. First Moderna vaccine doses arrive in Italy. https://www.ansa.it/english/news/general_news/2021/01/12/first-moderna-vaccine-doses-arrive-in-italy_ce39273f-aa51-4d55-9f8b-d5c658633007.html (2021).

    Not in our library

17. 17.

    Reuters. Italy kicks off vaccinations against COVID-19 in Rome. https://www.reuters.com/article/health-coronavirus-italy-vaccine/italy-kicks-off-vaccinations-against-covid-19-in-rome-idUKL1N2J703O (2020).

    Not in our library

18. 18.

    Ministero della salute (Italian Ministry of Health). Vaccinazione anti-SARS-CoV-2/COVID-19: PIANO STRATEGICO: Elementi di preparazione e di implementazione della strategia vaccinale. https://www.vaccinarsinsardegna.org/assets/uploads/files/378/piano-strategico-vaccinazione-anti-covid19.pdf (2020).

    Not in our library

19. 19.

    Presidenza del Consiglio dei Ministri. Ministero della Salute. Commissario Straordinario Covid-19. Report Vaccini Anti COVID-19. https://www.governo.it/it/cscovid19/report-vaccini/ (2021).

    Not in our library

20. 20.

    Priesemann V, et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet. 2021;397:92-93.

    Not in our library10.1016/s0140-6736(20)32625-8

21. 21.

    Priesemann V, et al. An action plan for pan-European defence against new SARS-CoV-2 variants. Lancet. 2021;397:469-470.

    Not in our library10.1016/s0140-6736(21)00150-1

22. 22.
    Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England · 2021

    No notice
23. 23.

    Abbott, S., Funk, S. & CMMID COVID-19 Working Group. Local area reproduction numbers and S-gene target failure. https://cmmid.github.io/topics/covid19/local-r-sgtf.html (2021).

    Not in our library

24. 24.

    Horby, P. et al. NERVTAG note on B.1.1.7 severity. https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117 (2021).

    Not in our library

25. 25.
    Model-informed COVID-19 vaccine prioritization strategies by age and serostatus · 2021

    No notice
26. 26.

    Ramos A. M., Vela-Pérez, M., Ferrández, M. R., Kubik, A. B. & Ivorra, B. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. Preprint at ResearchGate 10.13140/RG.2.2.32580.24967/2 (2021).

    Not in our library10.1016/j.cnsns.2021.105937

27. 27.

    Grundel, S. et al. How to coordinate vaccination and social distancing to mitigate SARS-CoV-2 outbreaks. Preprint at medRxiv10.1101/2020.12.22.20248707 (2020).

    Not in our library

28. 28.

    Ministero della Salute. Vaccinazione anti-SARS-CoV-2/COVID-19, Piano Strategico, elementi di preparazione e di implementazione della strategia vaccinale. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2986_allegato.pdf (2020).

    Not in our library

29. 29.

    Kissler SM, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860-868.

    Not in our library10.1126/science.abb5793

30. 30.

    Bin M, et al. Post-lockdown abatement of COVID-19 by fast periodic switching. PLoS Comput. Biol. 2021;17:e1008604.

    Not in our library10.1371/journal.pcbi.1008604

31. 31.

    Tetteh, J. N. A., Nguyen, V. K. & Hernandez-Vargas, E. A. COVID-19 network model to evaluate vaccine strategies towards herd immunity. Preprint at medRxiv10.1101/2020.12.22.20248693 (2020).

    Not in our library10.1016/j.jtbi.2021.110894

32. 32.
    Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 · 2021

    No notice
33. 33.

    Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet397, 952–954 (2021).

    Not in our library10.1016/s0140-6736(21)00370-6

34. 34.

    Callaway, E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature589, 177–178 (2021).

    Not in our library10.1038/d41586-021-00031-0

35. 35.

    Burki T. Understanding variants of SARS-CoV-2. Lancet. 2021;397:462.

    Not in our library10.1016/s0140-6736(21)00298-1

36. 36.

    Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2—what do they mean? JAMA. 2021;325:529-531.

    Not in our library10.1001/jama.2020.27124

37. 37.

    Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 10.1056/NEJMoa2102214 (2021).

    Not in our library10.1056/nejmoa2102214

38. 38.

    Lopez Bernal, J. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. Preprint at medRxiv10.1101/2021.03.01.21252652 (2021).

    Not in our library

39. 39.

    GOV.UK. Coronavirus (COVID‑19). https://www.gov.uk/coronavirus

    Not in our library

40. 40.

    Widge AT, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 2021;384:80-82.

    Not in our library10.1056/nejmc2032195

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.